Brise raises $20M; Taro shareholder criticizes Sun Pharma deal
Plus, news about Tarsus Pharmaceuticals and Biohaven: Brise Pharmaceuticals raises $20M: The funding comes from Shunxi Fund, Sherpa Healthcare Partners and Qiming Ventures, among other investors. The...
View ArticleClik here to view.
Novartis’ simplified strategy takes shape as the company seeks former Bristol...
Novartis appears headed in the right direction now that Sandoz has been spun out, operations have been streamlined and the Swiss company is reporting higher-than-expected sales for several medicines....
View ArticleMarketingRx roundup: Cannes ad festival speakers to include Pfizer, Novo...
Pharma companies set for Cannes ad creativity festival: Pfizer and Novo Nordisk are both set to take the main stages at Cannes’ advertising confab this summer. The just-announced program highlights...
View ArticleGNI Group to form $100M fund with Chinese state-owned enterprises
China’s GNI Group announced on April 18 that it has signed an agreement with Chinese state-owned enterprises and state-invested enterprises to form a $100 million fund. The fund name is “GNI...
View ArticleShimadzu Corporation establishes three R&D centers in the US in anticipation...
Japan’s Shimadzu Corporation announced this month that its US subsidiary, Shimadzu Scientific Instruments (SSI), has established a new R&D center in the US, and is planning to strengthen its...
View ArticleClik here to view.
Flagship’s gene editing startup Tessera cuts jobs as it shifts resources to...
Tessera Therapeutics, Flagship’s major bet on what it calls gene writing, is letting go 13% to 14% of its workforce, a spokesperson confirmed to Endpoints News. The well-funded Boston biotech will...
View ArticleClik here to view.
Vertex licenses TreeFrog’s tech to upscale cell therapy manufacturing for...
Vertex will pay $25 million upfront for TreeFrog Therapeutics’ cell manufacturing technology that can help boost production of its early-phase type 1 diabetes assets. In exchange for an exclusive...
View ArticleInizio Evoke Comms taps Stephanie DeViteri in return to agency as president
Stephanie DeViteri is taking over as Inizio Evoke Comms’ president for North America, returning to the agency where she spent 20 years after a two-year stint running the healthcare practice at MSL. She...
View ArticleClik here to view.
FDA gives accelerated approval to Day One’s targeted treatment for most...
The FDA granted accelerated approval to Day One Biopharmaceuticals’ pediatric brain tumor treatment. The regulator on Tuesday approved tovorafenib, taking place more than five years after Day One was...
View ArticleNovartis brings Lutathera to adolescents with rare cancer in first for...
Novartis’ Lutathera is now the first radiopharmaceutical approved for adolescents with a rare cancer found in the gut. The radioligand therapy won a label expansion on Tuesday for patients 12 years and...
View ArticleFlindr Therapeutics attracts J&J support for cancer pipeline in $21M Series A
Flindr Therapeutics has secured €20 million ($21 million) in a Series A raise aimed at advancing its lead program through an IND application and growing its pipeline of small-molecule cancer drugs. The...
View ArticleRoche doubles down on high-impact projects after slashing 20% of its pipeline
Roche has axed one-fifth of its pipeline since the third quarter of 2023 as part of a broader portfolio review aimed at boosting the company’s focus on high-impact projects. “We’ve taken out 20% of our...
View ArticleClik here to view.
Biogen details Leqembi's gradual commercial ramp-up
Biogen recorded higher-than-expected revenue for the lead rare disease drug from its $7 billion acquisition of Reata Pharmaceuticals, but the rollout of its second-generation Alzheimer’s drug with...
View ArticleEndeavor BioMedicines snags $132M for Phase 2 fibrosis drug, ADC candidate
San Diego biotech Endeavor BioMedicines is on a tear. The startup has secured a $132.5 million Series C after hiring four C-suite leaders, licensing an antibody-drug conjugate and revealing Phase 2a...
View ArticleClik here to view.
Samsung Bio’s bet on Plant 4 continues to pay off with first-quarter earnings...
Samsung Biologics’ Plant 4 remains a worthwhile $2 billion investment. The CDMO said that the facility was key in its first-quarter gains and will continue to be for the rest of the year. Although the...
View ArticleCentessa's public offering; Vivoryon ends Phase 2 Alzheimer’s trial
Plus, news about EXO Biologics: Centessa prices public offering: The startup aims to raise $93.5 million, or up to $107.6 million if all options are exercised. The funding would extend its runway into...
View ArticleDrug and biotech companies join lobbying push on China bill as scrutiny of...
Almost 20 biopharma and life sciences companies have registered to lobby on a bill that could ban US companies from working with Chinese life sciences contractors, according to federal records. Since...
View ArticleModerna collaborates with OpenAI to use ChatGPT tech in drugmaking
Moderna has teamed up with OpenAI to bring its GPT technology to drug development. The collaboration, which a Moderna spokesperson said began in May 2023 and was not disclosed previously, has allowed...
View ArticleBiogen details Leqembi and Skyclarys rollouts, eyes licensing deals and sells...
Biogen’s leaders defended their Eisai-partnered Leqembi during a first-quarter earnings update on Wednesday, saying the Alzheimer’s treatment is on a path to greater uptake as more patients started...
View ArticleClik here to view.
CureVac to cut costs, starts GSK-partnered bird flu vaccine trial
CureVac, once a player in the Covid-19 vaccine race, announced that it plans to reduce costs across the company. It said Wednesday that it enacted in March a program for employees to voluntarily leave...
View Article